学术简历
医学博士后（浙江大学）
医学博士（浙江大学）
药学学士（浙江大学）
浙江大学博士及博士后，新疆医科大学高层次引进人才，目前担任基础医学院教师。亚森老师主要研究方向是细胞应激性干预对蛋白质稳态的调控作用机制及其在肿瘤治疗中的应用，聚焦复发难治性肿瘤（血液肿瘤及实体瘤）的耐药机制及其应对策略研究。主持国自然青年基金1项和中国博士后面上基金2项。目前以第一或通讯作者身份发表SCI文章14篇和2个专业书籍章节，以主要参与作者身份发表SCI文章8篇，文章累计他引次数200多次。最近5年研究成果登上Research, Blood Cancer Discovery, Cancer Discovery, National Science Review, Acta Pharmacologica Sinica等国际权威高水平刊物。同时担任Cancer Research, Metallomics，Toxicology and Applied Pharmacology，Frontiers系列期刊，MDPI系列期刊等众多国际SCI刊物的审稿人。
社会兼职
暂无
主要承担和参与的课题（5-6项代表性课题）
1.国自然青年科学基金（82000155），NCoRs参与热激诱导PML/RARα融合蛋白降解的分子机制及热激与砷剂的协同作用研究，2021.01-2023.12，主持。
2.中国博士后科学基金第67批面上资助，（2020M671765），2020.06-2021.06，主持。
3.中国博士后科学基金第70批面上资助，2021M702877，2021.12-2023.06，主持。
4.浙江省自然科学基金重大项目，靶向降解新型冠状病毒RdRp转录复合体的创新研究、2022-2024、在研、参与。
5.国家自然科学基金面上项目，PML-RARα融合蛋白B-box2结构域点突变导致APL砷剂耐药的分子机制研究, 2022-2025、在研、参与。
6.浙江省领军型创新创业团队，白血病转化研究团队、2020-2024、在研、参与。
近期发表的主要文章
1. Maimaitiyiming Y#, Wang QQ#, Yang C#, Ogra Y, Lou Y, Smith CA, Hussain L, Shao YM, Lin J, Liu J, Wang L, Zhu Y, Lou H, Huang Y, Li X, Chang KJ, Chen H, Li H, Huang Y, Tse E, Sun J, Bu N, Chiou SH, Zhang YF, Hua HY, Ma LY, Huang P, Ge MH, Cao FL, Cheng X, Sun H, Zhou J, Vasliou V, Xu P, Jin J, Bjorklund M, Zhu HH, Hsu CH*, Naranmandura H* (2021). Hyperthermia Selectively Destabilizes Oncogenic Fusion Proteins.Blood Cancer Discovery. 11;2(4):388-401. doi: 10.1158/2643-3230.BCD-20-0188.
2. Maimaitiyiming Y#, Yang T#, Wang QQ#, Feng Y, Chen Z, Bjorklund M, Wang F, Hu C*, Hsu CH*, Naranmandura H* (2022). Heat Treatment Promotes Ubiquitin-Mediated Proteolysis of SARS-CoV-2 RNA Polymerase and Decreases Viral Load. Research. 2022, 9802969.https://doi.org/10.34133/2022/9802969
3. Wang L#, Zhan G#, Maimaitiyiming Y#, Su Y, Lin S, Liu J, Su K, Lin J, Shen S, He W, Wang F, Chen J, Sun S, Xue Y, Gu J, Chen X, Zhang J, Zhang L, Wang Q, Chang KJ, Chiou SH, Björklund M, Naranmandura H*, Cheng X*, Hsu CH* (2022). m6A Modification Confers Thermal Vulnerability to HPV E7 Oncotranscripts via Reverse Regulation of its Reader Protein IGF2BP1 upon Heat Stress. Cell Reports (Cover Story). 41(4):111546. doi:10.1016/j.celrep.2022.111546 (#Co-first Author)
4. Wang QQ#, Hussain L#, Yu PH, Yang C, Zhu CY, Ma Y, Wang SC, Yang T, Kang Y, Yu WJ, Maimaitiyiming Y*, Naranmandura, H* (2022). Hyperthermia Promotes Degradation of the Acute Promyelocytic Leukemia Driver Oncoprotein ZBTB16/RARα. Acta Pharmacologica Sinica. In press. (*共同通讯)
5. Yang T, Wang SC, Ye LY, Maimaitiyiming Y*, Naranmandura H*. (2023) Targeting Viral Proteins for Restraining SARS-CoV-2: Focusing Lens on Viral Proteins Beyond Spike for Discovering New Drug Targets. Expert Opinion On Drug Discovery. In press. (*共同通讯)
6. Bercier P#, Wang Q.Q#，Zang N#, Zhang J, Yang C, Maimaitiyiming Y, Abou-Ghali M, Berthier C, Wu C, Niwa-Kawakita M, Dirami T, Geoffroy M, Ferhi O, Quentin S, Benhenda S, Ogra Y, Gueroui Z, Zhou C*,Naranmandura H*, De The H*, and Lallemand-Breitenbach V*. (2023) Structural basis of PML/RARA oncoprotein targeting by arsenic unravels a cysteine rheostat controlling PML body assembly and function. Cancer Discovery. In Press. 10.1158/2159-8290.CD-23-0453
7. Lin J#, Zhan G#, Liu J#, Maimaitiyiming Y, Deng Z, Li B, Su K, Chen J, Sun S, Zheng W, Yu X, He F, Cheng X, Wang L, Shen B, Yao Z, Yang X, Zhang J, He W, Wu H, Naranmandura H, Chang KJ, Min J, Ma J, B. Mikael, Xu P*, Wang F*, Hsu CH* (2023). YTHDF2-mediated regulations bifurcate BHPF-induced programmed cell deaths. National Science Review. In press.https://doi.org/10.1093/nsr/nwad227.
8. Maimaitiyiming Y, Ye L, Yang T, Yu W, Naranmandura H (2022). Linear and Circular Long Non-Coding RNAs in Acute Lymphoblastic Leukemia: From Pathogenesis to Classification and Treatment. International Journal of Molecular Sciences. 23(8):4442. https://doi.org/10.3390/ijms23084442
9. Maimaitiyiming Y, Wang QQ, Hsu CH, Naranmandura H (2020). Arsenic induced epigenetic changes and relevance to treatment of acute promyelocytic leukemia and beyond.Toxicology and Applied Pharmacology. 406:115212. doi: 10.1016/j.taap.2020.115212.
10. Maimaitiyiming Y, Zhu HH, Yang C, Naranmandura H (2020). Biotransformation of arsenic trioxide by AS3MT favors eradication of acute promyelocytic leukemia: revealing the hidden facts. Drug Metabolism Reviews. 52(3):425-437. doi:10.1080/03602532.2020.1791173
11. Maimaitiyiming Y, Shao YM, Chen WZ, Jiang Y, Bu N, Ma LY, Wang QQ, Lu XY, Naranmandura H (2019). Irreversibility of arsenic trioxide induced PML/RARα fusion protein solubility changes. Metallomics. 11(12):2089-2096. doi:10.1039/c9mt00220k
12. Maimaitiyiming Y, Wang C, Xu S, Islam K, Chen YJ, Yang C, Wang QQ, Naranmandura H (2018). Role of arsenic (+ 3 oxidation state) methyltransferase in arsenic mediated APL treatment: an in vitro investigation. Metallomics, 10(6), 828-837. doi:10.1039/c8mt00057c
13. Maimaitiyiming Y, Hong F, Yang C, Naranmandura H (2019). Novel insights into the role of aptamers in the fight against cancer. Journal of Cancer Research and Clinical Oncology. 145(4), 797-810. doi:10.1007/s00432-019-02882-7
14. Maimaitiyiming Y, Yang C, Wang Y, Hussain L, Naranmandura H (2019). Selection and characterization of novel DNA aptamer against colorectal carcinoma Caco‐2 cells. Biotechnology and Applied Biochemistry. 66(3), 412-418. doi:10.1002/bab.1737
15. Su Y#,Maimaitiyiming Y#,Wang L#, Cheng X*, Hsu CH* (2021). Modulation of Phase Separation by RNA: A Glimpse on N6-Methyladenosine Modification. Frontiers in Cell and Devlopmental Biology. 9:786454. (#Co-first Author)
16. Hussain L#, Maimaitiyiming Y#, Islam K, & Naranmandura, H (2019). Acute promyelocytic leukemia and variant fusion proteins: PLZF-RARα fusion protein at a glance. Seminars in Oncology. 46(2), 133-144. (#Co-first Author)
17. Hussain L, Maimaitiyiming Y, Su L, Wang QQ, Naranmandura H (2019). Phenylarsine Oxide Can Induce Degradation of PLZF-RARα Variant Fusion Protein of Acute Promyelocytic Leukemia.Chemical Research in Toxicology. 15;32(4):548-550.
18. Hussain L, Maimaitiyiming Y, Su L, Wang QQ, Naranmandura H (2019). Phenylarsine Oxide Can Induce Degradation of PLZF-RARα Variant Fusion Protein of Acute Promyelocytic Leukemia.Chemical Research in Toxicology. 15;32(4):548-550.
19. Li L, Zhao X, Abdugheni R, Yu F, Zhao Y, Ma BF, Yang Z, Li R, Li Y,Maimaitiyiming Y*, Mayila Maimaiti M* (2023). Gut Microbiota Changes Associated with Low-Carbohydrate Diet Intervention for Obesity.Open Life Sciences. In press. （*共通讯）
参编教材与论著
1. Wang L#, Maimaitiyiming Y#,Su K#, Hsu CH* (2021). RNA m6A Modification: A Mediator between Cellular Stresses and Biological Effects. Epitranscriptomics. RNA Technologies, vol 12. Springer, Cham. https://doi.org/10.1007/978-3-030-71612-7_13 (#共同一作, book chapter)
2. Zhan G, Liu J, Lin J, Chen J, Sun S,Maimaitiyiming Y*,Hsu CH* (2023). Multifaceted Functions of RNA m6A Modification in Modulating Regulated Cell Death.RNA Structure and Function.(#共通讯, book chapter)
研究生培养
1. 肿瘤（耐药）与免疫微环境
2. 表观遗传与肿瘤发生发展及耐药
3. 免疫药理
